Key result
Cardiovascular risk factors, not menopause, are linked to a ~55% decline in flow-mediated vasodilatation.
Why the study?
The impact of conventional cardiovascular risk factors, menopausal state, and sleep-disordered breathing on vascular impairment during menopausal transition was unclear.
Do cardiovascular risk factors and menopausal state impact vascular impairment during menopausal transition?
Cohort (n=89)
Do cardiovascular risk factors and menopausal state impact vascular impairment during menopausal transition?
p-value: p=< 0.001
Vascular function declines significantly over 10 years during the menopausal transition, driven by age and cardiovascular risk factors rather than menopausal state itself.
CV risk factors, not menopause, drive vascular decline in midlife women; leaves open whether targeted modification alters trajectories.
AIMS: The prevalence of cardiovascular diseases increases in women after menopause. The aim of the study was to determine the impact of conventional cardiovascular risk factors such as age, blood pressure, smoking, cholesterol, obesity, and glucose balance, but also menopausal state and sleep-disordered breathing on vascular impairment during menopausal transition. METHODS: 89 women initiated the study and 74 of them participated in the 10-year follow-up. Cardiovascular disease risk factor assessments, ultrasound measurements of brachial artery function, including nitroglycerin-mediated vasodilatation and flow-mediated endothelium-dependent vasodilation, and sleep studies were repeated at baseline and at 5-year and 10-year follow-ups. RESULTS: Over the study period, all the cardiovascular disease risk estimates increased. Both flow-mediated endothelium-dependent vasodilatation (decline 55 %) and nitroglycerin-mediated vasodilatation (decline 18 %) worsened over the 10 years (p < 0.001). Vascular function was not associated with menopausal state (determined with follicle stimulating hormone). Systolic blood pressure (p = 0.009) and smoking (p = 0.006) at baseline were negatively associated with nitroglycerin-mediated vasodilatation at 5-year follow-up and the use of hormonal therapy at 5-year follow-up was positively associated with concurrent nitroglycerin-mediated vasodilatation (p = 0.041). Intermittent nocturnal hypoxemia at baseline was associated with flow-mediated endothelium-dependent vasodilatation at 10-year follow-up (p = 0.043). High body mass index and impaired glucose balance at 5-year follow-up were associated with nitroglycerin-mediated vasodilatation decline at 10-year follow-up (p = 0.022 and p = 0.037, respectively). CONCLUSIONS: We demonstrate how cardiovascular risk factors and vascular function evolve during menopausal transition. Although menopause was not associated with vascular impairment, short-term improvement in vascular function was observed in those using menopausal hormonal therapy. Intermittent nocturnal hypoxemia, obesity and impaired glucose control are early predictors of vascular decline during postmenopause.
No takes yet. Share an insight, caveat, or question.
Aittokallio et al. (2023) conducted a cohort in Vascular impairment during menopausal transition (n=89). Menopausal transition and cardiovascular risk factors was evaluated on Vascular function (flow-mediated endothelium-dependent vasodilatation and nitroglycerin-mediated vasodilatation) (p=< 0.001). During a 10-year follow-up, flow-mediated and nitroglycerin-mediated vasodilatation declined by 55% and 18% respectively (p<0.001), associated with cardiovascular risk factors rather than menopause.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: